Naloxegol (Movantik ®) Provides Rapid and Sustained Improvement of Opioid-Induced Constipation Symptoms Irrespective of Opioid Dose

Naloxegol (Movantik), an oral peripherally acting mu-opioid receptor antagonist has demonstrated rapid relief of opioid-induced constipation (OIC) in patients with chronic non-cancer pain in two phase 3 trials (KODIAC 4/5; NCT01309841/NCT01323790). This analysis aims to characterize the OIC symptom burden and evaluate the efficacy of naloxegol in treating symptoms of OIC based on daily opioid dosages. This is the first naloxegol analysis based on a lower opioid dose cutoff of 100 MEU/day.

Source: Pain Management Nursing - April 1, 2023 Category: Nursing Authors: Charles McLeskey, Jeffrey Gudin, Jeremy Adler, Carol Rockett, Mansi Jamindar, Richard Rauck, Lynn Webster, Theresa Mallick-Searle Source Type: research